Janssen's anti-cancer drug Imbruvica, which has started to expand its benefit, has succeeded in setting standards for now.

The HIRA announced that it held the 8th Cancer Disease Review Committee in 2022 on the 21st and made the decision. Through this deliberation committee, Imbruvica has set benefit standards for monotherapy in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, who are 65 years of age or older and have never been treated before.

Since April 2018, Imbruvica has been receiving benefits for secondary therapy for recurrent and refractory chronic lymphocytic leukemia. Brukinsa, which challenged MCL benefit at this cancer screening, failed to set standards.